Compound ID | 1188
Class: DNA synthesis inhibitor
| Agent Type: | Synthetic; Small molecule; Direct acting; |
| Spectrum of activity: | Gram-positive |
| Mechanism of action: | DNA synthesis inhibitor. Binds to minor groove of DNA |
| Target Pathogen: | Active against resistant streptococci, staphylococci and enterococci |
| Description: | Ravic. M., Firmin. D., Suckling. C., Hunter. I., Lundberg. C., Jensen. K. "in vivo Antimicrobial Activity of MGB-BP-3, a New Class of Antibacterial Agent, in Murine Infection Models " Abstracts of the Interscience Conference on Antimicrobial Agents and Chemotherapy. 2015. |
| Institute where first reported: | MGB Biopharma |
| Year first mentioned: | 2015 |
| Highest development stage: | Phase 2 (NCT03824795) |
| Development status: | Active |
| External links: | |
| PubChem link: | https://pubchem.ncbi.nlm.nih.gov/compound/23730143 |
| Guide to Pharmacology: | MGB-BP-3 |
| Citation: | https://doi.org/10.1021/acsinfecdis.2c00445 |